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AUC0-24h: Area under the curve during 24 hours 
CD: Crohn’s disease 40 
CS: croscarmellose sodium 
CV: coefficient of variation 
ECCO: European Crohn’s and Colitis Organisation 
GI: gastrointestinal 
GISS: gastrointestinal simulation system 45 
GIT: gastrointestinal tract 
HPMC: hydroxypropyl methylcellulose 
IBD: inflammatory bowel disease 
MAN: mannitol 
MC: microcrystalline cellulose 50 
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MMX: Multi-Matrix system 
PEG: polyethylene glycol 
SSF: sodium stearyl fumarate  


























Up to 50% of Crohn’s disease and ulcerative colitis patients suffer from ileo-colonic 
inflammation. Topically delivered budesonide is an effective treatment but in vitro as well as 
clinical data suggest that oral formulations currently used in clinical practice are not optimal 80 
to treat the ileo-colon. The aim of this in vitro study was to develop ileo-colonic-targeted 
zero-order sustained-release tablets containing 3 mg or 9 mg budesonide. Targeted delivery 
was achieved by coating the tablets with the ColoPulse technology (ColoPulse 3 mg or 
ColoPulse 9 mg, respectively). Tablet were tested in a 10-h gastrointestinal simulation system 
for site-specific release, zero-order release kinetics (R2≥0.950), release rate, and completeness 85 
of release (≥80%). Release profiles of the novel formulations were compared with Entocort, 
Budenofalk, and Cortiment (budesonide MMX). ColoPulse 3 mg and 9 mg were targeted to 
the simulated ileo-colon, budesonide release was complete and in a sustained zero-order 
manner, and both formulations complied with a 6-month accelerated stability study. None of 
the formulations currently used in clinical practice targeted the ileo-colon. These in vitro 90 
results are discussed in light of clinical data. ColoPulse 3 mg and 9 mg are novel interesting 













Crohn’s disease (CD) and ulcerative colitis (UC) are debilitating inflammatory bowel diseases 
(IBD). Both are chronic diseases affecting the gastrointestinal tract (GIT) and are 
characterized by their relapsing behavior. CD is characterized by transmural inflammation 105 
and can affect the entire GIT whereas in UC the inflammation is limited to the mucosa and 
can affect the rectum and colon. The exact pathogenesis of IBD is not completely elucidated 
but it is thought to be the result of an aberrant immune response of a genetically susceptible 
host against the hosts commensal gut microflora. This abnormal immune response involves 
both branches of the innate and adaptive immune system (Foersch et al., 2013), both 110 
contributing to tissue injury as a result of excessive production of pro-inflammatory mediators 
such as interleukin (IL)-1β, IL-6, and tumor necrosis factor-alpha (TNF-α). A prolonged 
inflammatory response against the gut epithelium may result in epithelial injury and therefore 
could lead to increased exposure to the gut microflora, amplifying the immune response 
(Abraham and Cho, 2009; Baumgart and Sandborn, 2012; Danese and Fiocchi, 2011; Ungaro 115 
et al., 2017). Therefore, anti-inflammatory and immune suppressive drugs that attenuate the 
aberrant immune and inflammatory response are efficacious is IBD. The choice of treatment 
depends on disease severity and location. Therapy aims to induce and thereafter maintain 
remission (Gomollón et al., 2017; Harbord et al., 2017). Approximately 50% of CD patients 
suffer from ileo-colonic inflammation and up to 45% of UC patient suffer from extensive 120 
colitis in which the entire colon can be affected (Peppercorn and Kane, 2018; Ungaro et al., 
2017).  
 The European Crohn’s and Colitis Organisation (ECCO) states that oral budesonide is 
the first-line treatment for mild-to-moderately active ileo-colonic CD. Oral budesonide is 
currently only advised in left-sided and extensive UC if aminosalicylate therapy fails 125 
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(Gomollón et al., 2017; Harbord et al., 2017). Budesonide is a potent glucocorticosteroid 
possessing a broad range of anti-inflammatory properties (Clark, 2007; Prantera, 2013; Rhen 
and Cidlowski, 2005). Due to its extensive first-pass metabolism by the gut mucosa and liver, 
budesonide acts primarily topically in the GIT with substantially less systemic side effects 
compared to traditional glucocorticosteroid (Kuenzig et al., 2014; Rezaie et al., 2015; 130 
Sherlock et al., 2015). To achieve local drug delivery in the distal inflamed GIT, budesonide 
release from oral formulations must be modified. In addition, since the inflammation in IBD 
is more often than not diffuse, drug release should cover the entire inflamed region instead of 
just one site. This can only be realized through a sustained drug release profile targeting the 
inflamed region during gastrointestinal (GI) transit. However, a major disadvantage of this 135 
approach is incomplete drug release from the formulation due to faster transit times as a result 
of frequent bowel movements, which is a common symptoms of active IBD.  (Abraham and 
Cho, 2009; Baumgart and Sandborn, 2012; Ungaro et al., 2017).  
 Commercially available oral budesonide formulations apply different strategies to 
target the site of inflammation. Table 1 shows the oral budesonide formulations currently used 140 
in clinical practice (Kuenzig et al., 2014; Rezaie et al., 2015; Sherlock et al., 2015). These 
formulations are generally modified-release cores or granules coated with a pH-sensitive 
polymer. They intend to treat specific parts of the GIT. Table 1 shows that the in vitro data do 
not correlate well with the observed clinical data. In vitro-in vivo correlation is challenging 
and depends on several factors such as physiochemical properties of the drug, formulation, 145 
and type of in vitro model (Dressman and Reppas, 2000; Goyanes et al., 2015b; Lu et al., 
2011). However, in vitro as well as clinical data suggest that these formulations are not 
optimally suited to treat the entire ileo-colon in IBD. Furthermore, none of these formulations 
is suited to treat the colon descendens. These observations imply that a great portion of IBD 
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patients may benefit from a novel oral budesonide formulation that aims to treat the entire 150 
ileo-colon.   
The ColoPulse technology is an innovative coating that is characterized by the 
incorporation of a superdisintegrant in the coating matrix to yield fast and site-specific 
coating disintegration. This coating was developed to specifically target the ileo-colonic 
region in humans. Previously, we have shown with stable isotope experiments and through 155 
comparative profiling with the IntelliCap capsule that ColoPulse-coated tablets and capsules 
target the ileo-colon in healthy subjects as well as CD patients. Additionally, food and time of 
food intake did not substantially influence the targeting performance in healthy subjects and 
CD patients (Maurer et al., 2015, 2013, 2012, Schellekens et al., 2010, 2009).  
 The aim of this in vitro study was to develop novel zero-order sustained-release tablets 160 
containing 3 mg or 9 mg budesonide intended to treat the entire ileo-colon in IBD. The target 
product profile is given in table 2. The desired release profile was characterized by site-
specific drug release followed by a sustained release rate ensuring the treatment of left-sided 
colitis as well. The novel formulations were compared with all oral budesonide formulations 












Table 1: Overview of all oral budesonide formulations currently used in clinical practice for the treatment of 175 
IBD. 
Formulation Technology Intend to treat Clinical data In vitro data 









40% absorbed in 
ileum and colon 
ascendens (SmPC, 
2017a). 
80-90% released in 
jejunum. 10-20% in ileo-
colon. First-order release 
(Goyanes et al., 2015a; 
Klein et al., 2005). 
Budenofalk 3 mg 









70% absorbed in 
ileum and colon 
ascendens (SmPC, 
2017b). 
95% immediately released 
in distal jejunum/proximal 








Entire colon Only 42% initial 
tablet disintegration 
observed in ileum; 
96% of released 
dose absorbed in 
colon. However, 
released dose is 
highly variable and 
estimated to be 
small (Brunner et 
al., 2006). 
Slow and incomplete 
release. Only 7% to 30% 
of dose released in colon 
(Gareb et al., 2016; 
Goyanes et al., 2015a). 
 
 
Table 2: Target product profile for ColoPulse 3 mg and 9 mg budesonide formulations. The requirements to 
comply with the accelerated stability study (6 months at 40 °C/75% RH) were the same. 180 
Parameter Requirement 
Content 95-105% of dose 
Lag time ≤5% released at t240 min in GISS (end of simulated 
jejunum, start of simulated ileum) 
Completeness of releasea  ≥80% at t600 min in GISS (6 h in simulated ileo-
colon) 
Release kinetics Correlation coefficient: R2 ≥0.950b 
Uncoated tablet mass 300 mg 
Applied coatingc 5 mg/cm2 
Tablet shape Biconvex, round, 9 mm 
a: Desired release was 80% after 300 min at pH 6 for non-coated tablet cores (Ph. Eur., 2018a). 
b: To comply with zero-order release kinetics, coefficient was arbitrarily set to ≥0.950. 












Budesonide (Sofotec Almirall, Bad Homburg, Germany), methacrylic acid–methyl 
methacrylate copolymer 1:2 (Eudragit S100, Evonik, Essen, Germany), hydroxypropyl 
methylcellulose (HPMC, Sigma-Aldrich, St. Louis, USA), polyethylene glycol 6000 (PEG 195 
6000, Fagron, Capelle aan de IJssel, The Netherlands), sodium stearyl fumarate (SSF, JRS 
Pharma, Rosenberg, Germany), methanol (Biosolve, Dieuze, France), acetone, sodium 
hydroxide, hydrochloric acid 37% (VWR, Fontenay-sous-Bois, France), talc, potassium 
dihydrogen phosphate, sodium chloride (Spruyt-Hillen, IJsselstein, The Netherlands), 
croscarmellose sodium (CS, FMC, Brussels, Belgium), sodium dihydrogen phosphate 200 
dihydrate, disodium monohydrogen phosphate dihydrate (Merck, Darmstadt, Germany), 
microcrystalline cellulose (MC, DMV Fonterra Excipients, Foxhol, The Netherlands), 
mannitol (Roquette, Nord-Pas-de-Calais, France), Cortiment 9 mg (budesonide MMX, 
Ferring Pharmaceuticals, Hoofddorp, The Netherlands, lot LI114), Budenofalk 3 mg capsules 
(Dr. Falk Pharma Benelux B.V., Breda, The Netherlands, lot 16D18706L), Budenofalk 9 mg 205 
granules (Dr. Falk Pharma GmbH, Freiburg, Germany, lot 17A11778L), and Entocort 3 mg 
(Tillotts Pharma GmbH, Rheinfelden, Germany) were all used as received from their 
respective suppliers.  
 
2.2 Target product profile and product development 210 
 
The desired formulation was obtained by first developing different uncoated tablet cores 
containing 9 mg budesonide. Release profiles of these cores were tested in dissolution 
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medium pH 6, the assumed average pH of the colon (Freire et al., 2011; McConnell et al., 
2008; Nugent et al., 2001; Press et al., 1998; Schellekens et al., 2007). Subsequently, the same 215 
formulation containing 3 mg budesonide was produced and investigated to ensure similar 
release profiles for both doses. Both formulations were tested for tablet hardness and 
friability. Thereafter, both formulations were coated with the ColoPulse coating and release 
profiles were investigated in the gastrointestinal simulation system (GISS). Release profiles of 
the oral budesonide formulations currently used in clinical practice (table 1) were investigated 220 
in the GISS as well and compared to the novel formulations. Finally, stability and product 
integrity of the novel formulations were investigated in a 6-months accelerated stability study 
(ICH, 2003). 
Table 3 shows the composition of the different formulations. HPMC was used as the 
polymer hydrogel matrix for the sustained release of budesonide. It is cheap, easy to process, 225 
and non-toxic and therefore a suitable excipient in controlled-release formulations (Li et al., 
2005). MAN and MC were respectively used as water-soluble and water-insoluble fillers as 
well as excipients to control budesonide release rate. Both excipients are cheap, have good 
flowability, and are widely applied in pharmaceutical formulations. SFF was added as the 
lubricant due to good blending characteristics, less sensitivity to overblending, and high 230 
degree of drug compatibility (JRS Pharma, 2018). The tablet cores with the desired release 
profile were coated with the ColoPulse coating to target the simulated ileo-colon (Maurer et 
al., 2013). 
  
2.3 Tablet cores 235 
 
Dry powder mixtures were blended in a Turbula mixer (Bachoven, Basel, Switzerland) at 90 
rpm. All excipients (except SSF) were mixed for 10 min. Subsequently, SSF was added and 
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mixed for an additional 2 min. Biconvex 9 mm tablets of 300 mg were compacted at 20 kN 
with a rate of 2 kN/s (Instron, Norwood, USA). 240 
 
Table 3: Composition of all the produced formulations. ColoPulse coating is expressed as mg Eudragit S100 per 
cm2. HPMC: hydroxypropyl methylcellulose. MAN: mannitol. MC: microcrystalline cellulose. SSF: sodium 
stearyl fumarate. 
Formulation Budesonide (mg) Excipients (%) ColoPulse coating 
10/90-HPMC/MAN 9 mg 9 9,5% HPMC, 89,5% MAN, 
1% SSF 
No 
10/90-HPMC/MC 9 mg 9 9,5% HPMC, 89,5% MC, 
1% SSF 
No 
15/85-HPMC/MAN 9 mg 9 14,5% HPMC, 84,5% 
MAN, 1% SSF 
No 
23/77-HPMC/MAN 3 mg 3 22,5% HPMC, 76,5% 
MAN, 1% SSF 
No 
23/77-HPMC/MAN 9 mg 9 22,5% HPMC, 76,5% 
MAN, 1% SSF 
No 
50/50-HPMC/MAN 9 mg 9 49,5% HPMC, 49,5% 
MAN, 1% SSF 
No 
ColoPulse 3 mg 3 22,5% HPMC, 76,5% 
MAN, 1% SSF 
5 mg/cm2 
ColoPulse 9 mg 9 22,5% HPMC, 76,5% 
MAN, 1% SSF 
5 mg/cm2 
 245 
2.4 Tablet coating 
 
Tablet cores were coated with the ColoPulse coating. The coating suspension consisted of 
Eudragit S100/PEG 6000/CS/talc in a ratio of 7/1/3/2 (w/w) in a solvent mixture of 
acetone/water 97/3 (v/v). First, PEG600 was gently heated until it was completely melted and 250 
acetone was added. This mixture was stirred until PEG 6000 dissolved in acetone. Thereafter, 
Eudragit S100 was added and dissolved in the mixture. Finally, CS and talc was added, 
resulting in the coating suspension. Tablet cores in a mini-rotating drum were continuously 
sprayed with the coating suspension. A hot air blower was aimed at the mini-rotating drum for 






2.5 Tablet hardness and friability tests 
 260 
Tablet hardness and friability were investigated for the uncoated and coated formulations with 
the desired release profiles. Tablet hardness was determined with a tablet hardness tester 
(Erweka, Heusenstamm, Germany). Friability was tested as described in the Ph. Eur. in a 
friability apparatus (Erweka, Heusenstamm, Germany). Twenty-two tablets (mass of 6.6 g) 
and 20 tablets (mass of 6.5 g)  were used per friability experiment for the uncoated and coated 265 
tablets, respectively (Ph. Eur., 2018b). 
 
2.6 Budesonide dissolution at pH 6 
 
An USP dissolution apparatus II (Sotax, Basel, Switzerland) was used for all dissolution 270 
experiments. Dissolution medium, medium temperature, and paddle speed were 1 L 
phosphate buffer pH 6 (67 nM), 37 ºC, and 50 rpm respectively. Before each experiment pH 
was measured, and if needed, adjusted to ensure the right pH. Budesonide release profiles of 
the produced formulation were determined by an online UV-VIS spectrophotometer (Thermo 




The GISS simulates GI transit in a simple in vitro model and is described in detail elsewhere 
(Schellekens et al., 2007).  It simulates transit through stomach (pH 1.2 for 2 h), jejunum (pH 280 
6.8 for 2 h), ileum (pH 7.5 for 30 min), and colon (pH 6 for 5.5 h). The same dissolution 
apparatus, medium temperature, and paddle speed were applied as described in section 2.6. 
Medium constituent and volume were variable as buffers were added for the pH change. 
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Initial volume was 500 mL (stomach) and end volume was 1000 mL (colon).  Before and 
during the experiments pH was measured, and adjusted if needed, to ensure the right pH. 285 
Budesonide release profiles from the ColoPulse formulations were determined by an 
online UV-VIS spectrophotometer equipped with 10-mm cuvettes measured at a wavelength 
of 247 nm. Budesonide release profiles from the commercially available formulations were 
determined by reversed-phase HPLC (Zorbax Extend-C18, Agilent Technologies, USA) 
coupled to UV detection (Dionex, Germering, Germany) since the formulation excipients 290 
interfered with UV-VIS analysis (data not shown). Wavelength, injection volume, flow rate, 
column temperature, run time, and mobile phase were 244 nm, 50 µL, 1.0 ml/min, 22 ºC, 5 
min, and methanol/water 80/20 (v/v), respectively. 
 
2.8 Accelerated stability study 295 
 
ColoPulse tablets containing 3 mg or 9 mg budesonide packed in polypropylene containers 
were placed at 40 ºC and 75% RH. Tablets were tested for content and release profile in the 
GISS at t0 months, t3 months, and t6 months (ICH, 2003). The requirements to comply with 
the stability study are depicted in table 2. GISS experiments were conducted as described in 300 
section 2.7. For the content analysis, a tablet was placed in a 500.0-ml volumetric flask filled 
with methanol/water 80/20 (v/v). This was stirred overnight, filtered through a 0.45-µm filter, 
and analyzed by the HPLC method described in section 2.7. 
 
2.9 Calculations 305 
 
The correlation coefficient (R2) was calculated by the least squares methods. R2 was 
calculated from t0 min till t300 min for the dissolution experiments at pH 6. R2 was calculated 
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from the first point (0% release) before initial release was observed till t600 min during the 




3.1 Tablet cores 
 315 
Figure 1 shows the release profiles of the five different formulations containing 9 mg 
budesonide in dissolution medium pH 6. Table 4 summarizes the release characteristics of 
these formulations. The release profiles of 10/90-HPMC/MAN 9 mg and 15/85-HPMC/MAN 
9 mg showed complete budesonide release from these formulations but could not be classified 
as zero-order (86% release with R2=0.520 and 89% release with R2=0.836, respectively). The 320 
release profile of 50/50-HPMC/MAN could be classified as zero-order (R2=1.00). However, 
budesonide release from this formulation was slow and incomplete (30%). Budesonide release 
from 10/90-HPMC/MC 9 mg was the lowest (16%) and could not be classified as zero-order 
(R2=0.886).  Formulation 23/77-HPMC/MAN 9 mg had the desired release profile as release 
was complete (81%) and could be classified as zero-order (R2=0.954). The 3 mg budesonide 325 
core with the same formulation (23/77-HPMC/MAN 3 mg) showed similar release 
characteristics. Budesonide release from this formulation was complete (100%) and could be 
classified as zero-order (R2=0.989) as well. Both formulations 23/77-HPMC/MAN 9 mg and 
23/77-HPMC/MAN 3 mg complied with the friability tests and tablet hardness was on 
average 202 N (range 195-210 N). 330 
The 23/77-HPMC/MAN 3 mg and 23/77-HPMC/MAN 9 mg formulations were coated 
with 5 mg/cm2 of ColoPulse coating, resulting respectively in the ColoPulse 3 mg and 
ColoPulse 9 mg formulations.  
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[INSERT FIGURE 1 HERE] 
 335 
Table 4: Summary of the release characteristics of the different produced tablet cores. Release profiles are shown 
in figure 1. t300 min: mean±SD (n=3) percentage of budesonide dose released at time point 300 min. R2: 
correlation coefficient. N.a.: not applicable. 
Formulation R2 t300 min (%) Hardness (N)a Friability (%)b 
10/90-HPMC/MAN 9 mg 0.520 86±2 N.a N.a. 
10/90-HPMC/MC 9 mg 0.886 16±6 N.a N.a. 
15/85-HPMC/MAN 9 mg 0.836 89±3 N.a N.a. 
23/77-HPMC/MAN 3 mg 0.989 100±3 200 (195-205) 0.08 
23/77-HPMC/MAN 9 mg 0.954 81±4 204 (197-210) 0.10 
50/50-HPMC/MAN 9 mg 1.00 30±1 N.a N.a. 
a: average (range). 




Figure 2 shows the release profiles of ColoPulse 3 mg, Entocort 3 mg, and Budenofalk 3 mg 
in the GISS. Table 5 summarizes the release characteristics of these formulations. ColoPulse 345 
3 mg did not release any budesonide in the simulated stomach and release in the simulated 
jejunum was negligible (3%). Coating disintegration in the simulated ileum was rapid and 
complete, resulting in zero-order sustained-release (R2=0.988) of budesonide throughout the 
entire simulated ileo-colon. Release in the simulated ileum and colon was respectively 17% 
and 84%. The release was complete (104%) with a constant release rate of 0.5 mg/h. This 350 
formulation complied with the friability test and had an average hardness of 423 N (table 6). 
Release from Entocort 3 mg started in the simulated jejunum and was not zero-order 
(R2=0.733). Release before the simulated ileum was 77% and only 24% of the dose was 
released in the simulated ileo-colon with a time-dependent release rate. Budesonide release 
from Budenofalk 3 mg in the simulated stomach was negligible (2%). This formulation 355 
released 17% in the simulated jejunum. In the simulated ileum, the bulk of the dose (74%) 
was immediately released. Consequently, no substantial release was observed in the simulated 
colon. Release from Budenofalk 3 mg was not zero-order (R2=0.781). 
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Figure 3 shows the release profiles of ColoPulse 9 mg, Budenofalk 9 mg, and 
Cortiment 9 mg in the GISS. Table 5 summarizes the release characteristics of these 360 
formulations. Release from ColoPulse 9 mg before the simulated ileum was negligible (2%). 
Release started in the simulated ileum and was zero-order (R2=0.980) and sustained 
throughout the entire simulated ileo-colon. In the simulated ileum, 9% was released whereas 
74% was released in the simulated colon. Release was complete (85%) with a constant release 
rate of 1.2 mg/h. This formulation complied with the friability test and had an average 365 
hardness of 424 N (table 6). Budenofalk 9 mg had, as expected, a similar non-zero-order 
(R2=0.798) release profile as Budenofalk 3 mg. This formulation also had negligible release 
in the simulated stomach (1%), released 12% in the simulated jejunum, and released the  
 
[INSERT FIGURE 2 HERE] 370 
[INSERT FIGURE 3 HERE] 
 
Table 5: Summary of release characteristics of the different formulations in the GISS. Release profiles are 
depicted in figure 2 and 3. Budesonide release is expressed as percentage (mean±SD) of dose released in 
simulated region (n=3). R2: zero-order correlation coefficient.  375 
Formulation R2 Stomach (%) Jejunum (%) Ileum (%) Colon (%) Total (%) 
Entocort 3 mg 0.733 1±0 76±2 16±5 8±4 101±5 
Budenofalk 3 mg 0.781 2±2 17±3 74±9 7±3 100±2 
ColoPulse 3 mg 0.988 0±0 3±0 17±2 84±3 104±3 
Cortiment 9 mg 0.984 0±0 0±0 0±0 6±1 6±1 
Budenofalk 9 mg 0.798 1±0 12±0 69±7 11±4 93±4 
ColoPulse 9 mg 0.980 0±0 2±0 9±1 74±3 85±4 
 
majority of the dose (69%) immediately in the simulated ileum with only 11% release in the 
simulated colon. Cortiment 9 mg had the lowest and slowest release. Substantial release (5%) 
was observed at t=540 min, 4.5 h in the simulated colon. Release at the end of the experiment 
was 6% and release after 24 h in the GISS was 20% (data not shown). Although release was 380 




3.3 Accelerated stability study  
 
Figures 4 and 5 show the release profiles of ColoPulse 3 mg and 9 mg from the accelerated 385 
stability study. Table 6 summarizes the release characteristics, content, friability, and 
hardness results of these formulations. The release profiles of ColoPulse 3 mg as well as 
ColoPulse 9 mg did not differ substantially at t0 months, t3 months, and t6 months. Release 
started in the simulated ileum and showed zero-order release kinetics (range R2=0.975-0.988) 
throughout the simulated ileo-colon. Furthermore, release was complete (range 81-104%) for 390 
both formulations. Tablet hardness and friability did not change substantially during the 
stability study. Finally, all content values during the different time points were within the 95-
105% range.  
 
[INSERT FIGURE 4 HERE] 395 
[INSERT FIGURE 5 HERE] 
 
Table 6: Summary of the release characteristics (n=3), content (n=3), friability, and hardness results (n=3) of 
ColoPulse 3 mg and 9 from the accelerated 6-month stability study at 40 ºC/75% RH. R2: correlation coefficient. 
t240 min: mean±SD percentage of budesonide dose released at time point 240 min (end of simulated jejunum, 400 
start of simulated ileum). t600 min: mean±SD percentage of budesonide dose released at time point 600 min 
(end of experiment, 6 h in simulated ileo-colon). 









3 mg t0 months 102 (101-103) 0.988 3±1 104±3 423 (412-
430) 
0.06 
3 mg t3 months 100 (98-103) 0.984 3±2 102±9 430 (419-
445) 
0.05 
3 mg t6 months 100 (97-101) 0.984 1±0 95±5 436 (429-
442) 
0.05 
9 mg t0 months 102 (100-104) 0.980 2±0 85±4 424 (410-
436) 
0.05 
9 mg t3 months 100 (98-102) 0.975 1±1 80±4 432 (421-
444) 
0.07 
9 mg t6 months 100 (100-101) 0.979 1±0 81±1 429 (425-
436) 
0.06 
a: average value as percentage of dose (range) 
b: average (range) 





The results showed that the newly developed ColoPulse 3 mg and 9 mg formulations met the 
target product profile (table 2). In view of treating ileo-colonic IBD, both formulations 
showed superior in vitro release profiles compared with the oral budesonide formulations 410 
currently used in clinical practice. The novel formulation was cheap and easy to produce from 
commonly applied excipient and complied with the accelerated stability study, making it a 
feasible new treatment option for ileo-colonic IBD.     
 Budesonide release from the different tablet cores could be modified by varying type 
and amount of excipients. Zero-order sustained and complete release was achieved by the 415 
formulation containing 23% HPMC and 77% MAN. This core formulation had a hardness of 
202 N, which increased noticeably after coating. Comparing the release profiles of 10/90-
HPMC/MC 9 mg and 10/90-HPMC/MAN 9 mg shows that replacing the insoluble MC by the 
soluble MAN substantially increased the budesonide release rate. Budesonide dissolution 
from 10/90-HPMC/MAN 9 mg was faster and more complete compared to 9 mg non-420 
formulated budesonide (data not shown), even though the former contained the gel former 
HPMC. It is assumed that MAN hydration and dissolution combined with the water in the 
HPMC gel matrix aided in the wetting and solvation of the lipophilic budesonide.  
The novel ColoPulse 3 mg and 9 mg formulations had similar release profiles. 
Negligible budesonide release before the simulated ileum was observed, indicating targeted 425 
delivery to the simulated ileo-colonic region. Furthermore, release was complete with a 
constant release rate throughout the simulated ileo-colon. The majority of the dose was 
released in the simulated ileo-colon (101% and 83% respectively). Both formulations 
complied with all the requirements set for the accelerated stability study and product integrity 
was shown by hardness and friability tests. The in vitro data indicate that this formulation 430 
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would be suitable to treat ileo-colonic IBD. Additionally, since release rate was constant and 
substantial throughout the simulated ileo-colon, the formulations might be used to treat left-
sided UC, a disease currently treated with enemas (Harbord et al., 2017).  Enemas have been 
associated with poor patient adherence and acceptance and oral treatment may therefore be 
more suitable for these patients (Cohen, 2006). 435 
The in vitro results showed that none of the oral budesonide formulations currently 
used in clinical practice showed the optimal release profile for treating ileo-colonic IBD. 
Budenofalk 3 mg and 9 mg released a substantial amount of budesonide before the simulated 
ileum (~15%) and the majority of the dose (~70%) was released immediately in the simulated 
ileum, with only a small remainder of the dose released in the simulated colon. Although a 440 
different GI model was used, similar results have been reported elsewhere (Klein et al., 2005). 
Clinical data in accordance with these in vitro results have also been described (SmPC, 
2017b), rendering this formulation only suitable to treat the inflamed ileum and proximal part 
of the colon, which is in accordance with the indication for Budenofalk. 
Entocort 3 mg released budesonide after the simulated stomach with first-order release 445 
kinetics. The majority of the dose (77%) was released in the jejunum with the remainder 
released in the simulated ileum. Similar results have been observed elsewhere in different GI 
models (Goyanes et al., 2015a; Klein et al., 2005). However, clinical data show that 40% of 
the dose is absorbed in the ileum and colon ascendens, illustrating that in vitro results do not 
always correlate well with in vivo data (SmPC, 2017a). Still, only 40% of the dose reaching 450 
the ileum and colon ascendens is far from optimal in treating  the entire ileo-colon. This 
formulation would be better suited to treat IBD in which the small bowel, ileum, and/or colon 
ascendens are affected. This is partly in accordance with the indication for Entocort as it is not 
registered to treat the small bowel. 
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Release from Cortiment 9 mg was slow and incomplete. With a release rate of 0.10 455 
mg/h, only 20% of the dose was released after 24 h in the GISS. Slow and incomplete release 
has been observed as well in a dynamic in vitro model simulating GI transit (Goyanes et al., 
2015a). In this study, total budesonide release from Cortiment 9 mg was 50% after a 10-h 
experiment of which 30% was released in the simulated colon. The difference in budesonide 
release compared to the present study could be explained by the different model used, which 460 
simulated GI transit with different buffers, volumes, and regional pH as well as transit times. 
Although the dynamic in vitro model simulated in vivo GI transit more accurately, budesonide 
release from Cortiment 9 mg was still far from complete. This formulation uses the MMX 
technology consisting of lipophilic and hydrophilic excipients. We hypothesized that the 
lipophilic budesonide rather stays in the lipophilic parts instead of dissolving in the aqueous 465 
medium. This is supported by data showing fast and complete mesalazine dissolution—a 
readily water soluble drug—from Mezavant, which uses the same MMX technology (Gareb et 
al., 2016). 
Cortiment 9 mg intends to treat the entire colon during transit but the observed slow 
and incomplete release questions whether sufficient amounts of budesonide is released during 470 
transit to treat the inflamed area. More so as transit can be fast as a result of frequent bowel 
movements in active IBD. Clinical data show that the release from Cortiment 9 mg started in 
the ileum in only 42% of the investigated healthy subjects; release before the ileo-colonic 
region was observed as well. Furthermore, absorbed dose (AUC0-24h values), an indication of 
released dose, was highly variable (40% CV) (Brunner et al., 2006). Assuming linear 475 
pharmacokinetics for budesonide  and based on the AUC0-24h of intravenously administered 
budesonide, we calculated that the absorbed dose was on average 0.7 mg with a range of 0.2-1 
mg (Edsbäcker et al., 2003; Edsbäcker and Andersson, 2004). In case of complete release, it is 
expected that 0.9 mg budesonide is absorbed taking a bioavailability of 10% into account 
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(Edsbäcker and Andersson, 2004). The authors stated that 96% of the released Cortiment 9 480 
mg dose was absorbed in the colon but this does not provide any insight as to how much 
budesonide was actually released (in mg) in the colon and what parts of the colon were 
actually treated by the drug (proximal, distal, or entire colon). Clinical efficacy has been 
shown in mild-to-moderate UC. In these studies, Cortiment 9 mg was compared to Asacol, 
(Balzola et al., 2012) Entocort, (Travis et al., 2014) and placebo. The therapeutic advantage 485 
was modest and it can even be questioned why a glucocorticoid was compared to low dose 
mesalazine (2.4 g Asacol instead of 4.8 g) in moderately active UC or a budesonide 
formulation with a completely different release profile (Entocort, see figure 2 and 3) 
(Prantera, 2014; Prantera and Scribano, 2014; Sherlock et al., 2015). We therefore think that 
this formulation is not optimally suited to treat ileo-colonic IBD. 490 
The GI environment in humans is highly variable and complex. Moreover, this 
environment can be influenced by a plethora of factors such as the microbiome, sex, age, fed 
state, diseases, and drugs. GI fluid volume and composition, pH, and transit time vary greatly 
between and even within individuals. In humans, on average, the pH of the stomach is 1-2, 
which rises to 6.5-6.8 in the small bowel. Thereafter, pH rises for a short period of time to 7.5 495 
in the ileum after which it drops to 6.0-6.5 in the colon. During colonic transit, pH  rises 
slightly to 7. Similar pH values have been reported in IBD patients. GI transit times however 
are more variable and affected by disease state. This makes it impossible to accurately 
simulate the GI environment in vitro as there is not one GI environment (Freire et al., 2011; 
Graff et al., 2001; Haase et al., 2016; McConnell et al., 2008; Nugent et al., 2001; Press et al., 500 
1998; Sjögren et al., 2014; Varum et al., 2013).  
 Thus, the limitation of our study was the use of a simple in vitro model. This model 
applies standardized simple aqueous buffers of set volumes, pH values, and standardized 
transit times to simulate GI transit whereas these parameters can vary greatly in humans and 
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can affect drug dissolution from a given formulation. More so from a sustained-release 505 
formulation since a faster transit time could correspond to incomplete drug release and part of 
the dose excreted with the feces. In addition, no efforts were made to simulate the complex 
composition of GI fluids, which contain enzymes, bile salts, bacteria, and other electrolytes. 
The GISS does not reflect the complex and highly variable GI environment (Freire et al., 
2011; McConnell et al., 2008).  510 
However, during the first stages of product development it aids in formulating and the 
comparison of different release profiles. Even though the GISS is a simple in vitro model, we 
applied it for quality assurance of ColoPulse coating performance in several clinical trials. We 
have shown that ColoPulse coating performance in vitro correlates with coating performance 
in vivo, although this does not assure the same in vivo budesonide release profile from the 515 
novel formulations (Maurer et al., 2015, 2013, 2012, Schellekens et al., 2010, 2009). This 
should be investigated in a clinical trial. Therefore, we are currently preparing a clinical trial 
to investigate the efficacy and safety of the novel ColoPulse 3 mg and 9 mg budesonide 




Based on in vitro data, the novel ColoPulse 3 mg and 9 mg budesonide formulations had 
similar release profiles. The tablets started to release budesonide in the simulated ileum and 
release rate was constant throughout the entire simulated colon until drug release was 525 
complete. Furthermore, the formulations were shown to be stable. The in vitro results indicate 
that the oral budesonide formulations currently used in clinical practice were not optimally 
suited for the treatment of ileo-colonic IBD. The developed formulations are interesting 
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treatment options for ileo-colonic IBD. A clinical trial is needed to test the therapeutic 










8. Figure captions 540 
 
Figure 1: The release profiles of the different produced tablet cores (n=3) in dissolution 
medium pH 6. Budesonide release is expressed as percentage of the dose (mean±SD). 
Formulation composition is given in table 3. 
 545 
Figure 2: The release profiles of Entocort 3 mg (n=3), Budenofalk 3 mg (n=3), and ColoPulse 
3 mg (n=3) in the GISS. pH change over time is depicted as well. Budesonide release is 
expressed as percentage of the dose (mean±SD). 
 
Figure 3: The release profiles of Cortiment 9 mg (n=3), Budenofalk 9 mg (n=3), and 550 
ColoPulse 9 mg (n=3) in the GISS. pH change over time is depicted as well. Budesonide 




Figure 4: The release profiles of ColoPulse 3 mg (n=3) in the GISS at different time points 
during the accelerated stability study. pH change over time is depicted as well. Budesonide 555 
release is expressed as percentage of the dose (mean±SD). 
 
Figure 5: The release profiles of ColoPulse 9 mg (n=3) in the GISS at different time points 
during the accelerated stability study. pH change over time is depicted as well. Budesonide 
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ColoPulse 3 mg t0 (n=3) ColoPulse 3 mg t3 months 40 °C/75% RH (n=3)































































Colopulse 9 mg t0 (n=3) Colopulse 9 mg t3 months 40 °C/75% RH (n=3)
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Entocort 3 mg Budenofalk 3 mg ColoPulse 3 mg Cortiment 9 mg 
Budenofalk 9 mg ColoPulse 9 mg pH medium 
